Bispecific antibodies as monotherapy or in combinations for non-hodgkin B-cell lymphoma: latest updates from the American society of hematology 2022 annual meeting

Overview of attention for article published in Experimental Hematology & Oncology, April 2023

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (55th percentile)
Above-average Attention Score compared to outputs of the same age and source (61st percentile)

Mentioned by

twitter: 4 X users

Citations

dimensions_citation: 3 Dimensions

Readers on

mendeley: 4 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 2,733 followers.

RT @Lymphoma_Papers: Bispecific antibodies as monotherapy or in combinations for non-hodgkin B-cell lymphoma: latest updates from the Ameri…

23 Apr 2023

Reply Repost Favourite

RT @Lymphoma_Papers: Bispecific antibodies as monotherapy or in combinations for non-hodgkin B-cell lymphoma: latest updates from the Ameri…

23 Apr 2023

Reply Repost Favourite

RT @Lymphoma_Papers: Bispecific antibodies as monotherapy or in combinations for non-hodgkin B-cell lymphoma: latest updates from the Ameri…

22 Apr 2023

Reply Repost Favourite

Bispecific antibodies as monotherapy or in combinations for non-hodgkin B-cell lymphoma: latest updates from the American society of hematology 2022 annual meeting #lymphoma #lymsm https://t.co/q72kLeZc1D

22 Apr 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.